Register here to watch on-demand:

In this 60-minute interactive virtual exchange on Drug Repurposing — Perspective on an emerging pharmaceutical solution, we have Dr. Richard Mollard, MBA, Ph.D., Chief Scientific Officer,  PharmAust Ltd in the hot seat, along with Kenneth Barr,  Ph.D., Senior Vice President - Discovery Services, Syngene, and Host, Ashu Tandon, CCO, Syngene. 


Topics to be discussed are as follows:

  • Drug repurposing as an effective alternative approach to traditional Drug Discovery
  • Changing Landscape: Drug repurposing gaining considerable momentum
  • Steps in the Drug repurposing journey – moving to GMP scale
  • Australian Pharmaceutical Industry Landscape
  • Dynamics of working with an Indian CRO

© Syngene International Ltd.
Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase - IV, Bangalore 560099 India

Moderator: Ashu Tandon
Chief Commercial Officer, Syngene International Ltd.

Ashu has 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.

As a member of Syngene's Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Dr Richard Mollard PhD MBA has over 25 years of national and international experience in biomedical and pharma research design, product translation and business development. He has conducted small therapeutic molecule design in France and the US with Louis Pasteur University, Bristol Myers Squibb, the University of Michigan and Eli Lilly & Co.

Richard has consulted for public and private companies in Australia, Asia, the US and the UK assisting in raising over $100 million in capital. Richard consulted for PharmAust for three years prior to joining as CSO in 2017, and then as CEO of PharmAust’s fully-owned subsidiary, Pitney Pharmaceuticals Pty Ltd.
 

Panelist: Dr. Kenneth Barr, Ph.D.
Sr. Vice President – Discovery Services, Syngene International Ltd.

Kenneth has over two decades of experience in the areas of drug discovery for both small and large molecules and associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. 

Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations, FORMA Therapeutics. At FORMA, he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts and providing alliance management for key CRO relationships. Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology. He pursued his Postdoctoral study in Natural product synthesis from the University of Texas.

Moderator & Panelists for the session:

Panelist: Dr. Richard Mollard, MBA, Ph.D.
Chief Scientific Officer, PharmAust Ltd.